<DOC>
	<DOCNO>NCT01081613</DOCNO>
	<brief_summary>Inhibition Heat Shock Protein ( HSP ) 90 new , promising treatment modality cancer patient , particularly set resistance . A reliable read system ( biomarker ) evaluation early treatment effect great importance development treatment modality , could contribute customize treatment individual patient . So far , reliable biomarker describe HSP90 effect . Visualizing effect HSP90 vascular endothelial growth factor ( VEGF ) secretion vivo patient , whole body 89Zr-bevacizumab uptake , great importance respect , may contribute tailor made cancer treatment . The purpose present study evaluate effect HSP90 inhibition AUY922 VEGF mean 89ZR-bevacizumab PET .</brief_summary>
	<brief_title>Imaging HSP90 Inhibitor AUY922 VEGF-89ZR-bevacizumab Positron Emission Tomography ( PET )</brief_title>
	<detailed_description>This feasibility study design side study multicenter , international phase I-II trial HSP90 inhibitor AUY922 ( protocol CAUY922A2101 ) , part biomarker assessment . In protocol CAUY922A2101 , section 4 , design phase I-II trial described ( p37 , 38 ) . Briefly , dose-escalation study perform accord phase I design adult patient advance solid malignancy . This part follow dose-expansion study accord phase II design . In latter part , breast cancer patient enrol either refractory hormone- trastuzumab treatment ( treatment arm , n=40 patient ) , maximal tolerate dose AUY922 base phase I part study . Patients ER positive , hormone therapy refractory breast cancer , receive 89Zr-bevacizumab PET scan part present side study protocol , perform collaboration Royal Marsden Hospital ( United Kingdom ) . To end , 89Zr-bevacizumab PET scan perform ( baseline ) treatment HSP90 inhibitor AUY922 , describe . A minimum six patient entered evaluate whether effect HSP90 inhibition AUY922 detect 89Zr-bevacizumab PET scan</detailed_description>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>patient ER positive , hormone therapy refractory breast cancer participation phase III trial HSP90 inhibitor AUY922 ( exclusion criterion study AUY922 describe protocol CAUY922A2101 , Clinical Trials NCT00526045A . participation phase III trial HSP90 inhibitor AUY922</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>heat shock protein</keyword>
	<keyword>breast cancer</keyword>
	<keyword>PET image</keyword>
	<keyword>bevacizumab</keyword>
</DOC>